• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study.

作者信息

Paul Abhijit, Kadnur Harshith B, Ray Animesh, Chatterjee Samrat, Wig Naveet

机构信息

Complex Analysis Group, Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana, India.

Department of Medicine, All India Institute of Medical Science, New Delhi, India.

出版信息

J Family Med Prim Care. 2021 Nov;10(11):4030-4035. doi: 10.4103/jfmpc.jfmpc_830_21. Epub 2021 Nov 29.

DOI:10.4103/jfmpc.jfmpc_830_21
PMID:35136763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8797069/
Abstract

OBJECTIVE

The present study aims to predict the likelihood of and likely time required to attain herd immunity against COVID-19 in New Delhi due to natural infection.

METHOD

An ODE-based mathematical model was constructed by extending the classical SEIR model to predict the seroprevalence rate. We estimated the parameter values for Delhi using available data (reported cases and the seroprevalence rate) and used them for future prediction. Also, changes in the seroprevalence rate with different possibilities of reinfection were predicted.

RESULTS

Maximum seroprevalence rate obtained through our model is 31.65% and also a reduction in the seroprevalence rate was observed for the upcoming one month (month of January, 2021) due to the reduced transmission rate. After increasing the transmission rate to the value same as the third wave in New Delhi, we obtained a maximum value of 54.96%. This maximum value significantly decreased with the reduction in the reinfection possibilities. Also, a little impact of the duration of persistence of antibodies, 180 vs 105 days, was observed on the maximum seroprevalence.

CONCLUSION

This modelling study suggests that natural infection alone, as gauged by serial sero-surveys, may not result in attainment of herd immunity in the state of Delhi.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/b60916db0230/JFMPC-10-4030-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/bafb1d420649/JFMPC-10-4030-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/56b7c9c1024e/JFMPC-10-4030-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/11905cb9bc12/JFMPC-10-4030-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/b60916db0230/JFMPC-10-4030-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/bafb1d420649/JFMPC-10-4030-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/56b7c9c1024e/JFMPC-10-4030-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/11905cb9bc12/JFMPC-10-4030-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e27/8797069/b60916db0230/JFMPC-10-4030-g017.jpg

相似文献

1
Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study.
J Family Med Prim Care. 2021 Nov;10(11):4030-4035. doi: 10.4103/jfmpc.jfmpc_830_21. Epub 2021 Nov 29.
2
SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.黎巴嫩的 SARS-CoV-2 抗体血清阳性率:首次全国血清学调查结果。
BMC Infect Dis. 2022 Jan 10;22(1):42. doi: 10.1186/s12879-022-07031-z.
3
Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.利用血清流行率调查估计美国 SARS-CoV-2 感染、有症状感染、住院和死亡人数。
JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706.
4
Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India.印度新德里一家教学医院员工中新冠病毒抗体血清流行率及血清阳性预测因素
Osong Public Health Res Perspect. 2021 Apr;12(2):88-95. doi: 10.24171/j.phrp.2021.12.2.06. Epub 2021 Apr 29.
5
Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic.波兰波兹南在新冠疫情第一波流行后抗SARS-CoV-2抗体的流行情况
Vaccines (Basel). 2021 May 21;9(6):541. doi: 10.3390/vaccines9060541.
6
Critical interpretative synthesis of herd immunity for COVID-19 pandemic.关于新冠疫情群体免疫的批判性解释性综述
J Family Med Prim Care. 2021 Mar;10(3):1117-1123. doi: 10.4103/jfmpc.jfmpc_1127_20. Epub 2021 Apr 8.
7
Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.武汉封城期间当地疫区患者 SARS-CoV-2 抗体监测。
BMC Infect Dis. 2022 Jan 4;22(1):10. doi: 10.1186/s12879-021-07010-w.
8
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.美国中西部一公立学校系统工作人员中抗 SARS-CoV-2 IgG 抗体的血清阳性率。
PLoS One. 2021 Jun 10;16(6):e0243676. doi: 10.1371/journal.pone.0243676. eCollection 2021.
9
COVID-19: individual and herd immunity.COVID-19:个体和群体免疫。
C R Biol. 2021 Jun 21;344(1):7-18. doi: 10.5802/crbiol.41.
10
Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort Study.印度德里一家专门的三级护理新冠病毒医院医护人员中新冠病毒血清流行率及风险评估:一项队列研究
Cureus. 2021 Dec 29;13(12):e20805. doi: 10.7759/cureus.20805. eCollection 2021 Dec.

引用本文的文献

1
Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020.2020 年 8 月至 12 月美国俄亥俄州辛辛那提市 SARS-CoV-2 感染血清阳性率。
PLoS One. 2021 Jul 14;16(7):e0254667. doi: 10.1371/journal.pone.0254667. eCollection 2021.

本文引用的文献

1
Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.个体对 SARS-CoV-2 的易感性或暴露程度的差异降低了群体免疫阈值。
J Theor Biol. 2022 May 7;540:111063. doi: 10.1016/j.jtbi.2022.111063. Epub 2022 Feb 18.
2
Genomic evidence for reinfection with SARS-CoV-2: a case study.基因组证据表明 SARS-CoV-2 再次感染:一项案例研究。
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
3
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
COVID-19 患者血清和唾液中针对 SARS-CoV-2 刺突抗原的抗体反应持续存在。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe5511.
4
Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients.无症状和轻症新冠患者与肺炎型新冠患者中和抗体产生情况的比较
J Clin Med. 2020 Jul 17;9(7):2268. doi: 10.3390/jcm9072268.
5
Reconstruction of the full transmission dynamics of COVID-19 in Wuhan.重建 COVID-19 在武汉的完整传播动态。
Nature. 2020 Aug;584(7821):420-424. doi: 10.1038/s41586-020-2554-8. Epub 2020 Jul 16.
6
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
7
COVID-19 transmission through asymptomatic carriers is a challenge to containment.新型冠状病毒肺炎通过无症状携带者传播对疫情防控构成挑战。
Influenza Other Respir Viruses. 2020 Jul;14(4):474-475. doi: 10.1111/irv.12743. Epub 2020 Apr 15.
8
Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients.警惕 2019 年冠状病毒病患者在流行期间的非呼吸症状:一家三口均为无症状 COVID-19 患者的聚集性病例报告。
J Med Virol. 2021 Jan;93(1):518-521. doi: 10.1002/jmv.25776. Epub 2020 Sep 28.